Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What is the Predicted Annual Growth Rate of the Scleroderma Market Over the Coming Decade?
The scleroderma market has also seen strong growth, projected to rise from $2.33 billion in 2024 to $2.49 billion in 2025 at a CAGR of 6.9%. Key factors include advances in diagnosis, immunological research, therapeutic developments, increased awareness and education, and genetic studies.
The scleroderma market is projected to experience significant growth in the coming years, reaching $3.25 billion by 2029 at a CAGR of 6.9%. This growth is driven by advancements in biological therapies, precision medicine, stem cell treatments, genomic and biomarker research, and global partnerships. Key trends include digital health innovations, microbiome research, patient-centered care, regenerative medicine, and efforts to improve health equity and accessibility.
Which Drivers Are Expected to Have the Greatest Impact on the scleroderma Market’s Growth?
The increasing prevalence of scleroderma is expected to advance the scleroderma market moving forward. Scleroderma is a chronic autoimmune condition characterized by the excessive growth of collagen, a protein that forms the structural framework of the skin and other tissues. This condition arises from an unregulated immune response that may be triggered by various environmental factors. As cases increase, the need for enhanced diagnosis and treatment becomes clear. Therapeutics for scleroderma are vital for managing the disease and alleviating symptoms by modulating the immune response and reducing exposure to environmental risk factors. For instance, in June 2022, Karger Publishers, a peer-reviewed journal publisher based in Switzerland, reported that 19,000 individuals in the UK and 2.5 million globally had scleroderma. Furthermore, an August 2024 research article from the Oxford Academic Press, a university press affiliated with the University of Oxford in the UK, identified 1,588 cases of systemic sclerosis (SSc) out of 10.1 million individuals in the CPRD, resulting in the diagnosis of 206 cancers, predominantly mucocutaneous (4.5%), lung (2.1%), and breast (1.9%). Hence, the rising prevalence of scleroderma is driving the scleroderma market.
Get Your Free Sample of the Global Scleroderma Market Report Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12615&type=smp
What Are the Major Players Making an Impact in the Scleroderma Market’s Growth?
Major companies operating in the scleroderma market include:
• Pfizer Inc._x000D_
• Johnson And Johnson Inc._x000D_
• F. Hoffmann-La Roche AG_x000D_
• Abbvie Inc._x000D_
• Bayer AG_x000D_
Which Upcoming Trends Are Set to Influence the Scleroderma Market’s Path Forward?
Developing novel treatments is an emerging trend in the scleroderma market. Leading firms in this sector are working on innovative drugs to manage symptoms and sustain market growth. For instance, in April 2022, Tyr Pharma Inc., a US-based biotherapeutics company, received regulatory approval from the U.S. Food and Drug Administration for its novel drug efzofitimod, designed to treat systemic sclerosis-related interstitial lung disease. This first-in-class immunomodulator targets the neuropilin-2 (NRP2) receptor to regulate immune responses and reduce scleroderma symptoms. Efzofitimod also addresses the immune cells responsible for systemic sclerosis-associated interstitial lung disease (SSc-ILD) and pulmonary sarcoidosis, lowering pro-inflammatory markers and demonstrating effectiveness in clinical trials.
Get Instant Access to the Global Scleroderma Market Report with Swift Delivery!
https://www.thebusinessresearchcompany.com/report/scleroderma-global-market-report
What Are the Main Segments of the Scleroderma Market, and How Are They Evolving?
The scleroderma market covered in this report is segmented –
1) By Treatment: Medication, Surgery, Other Treatments
2) By Indication: Systemic Scleroderma, Localized Scleroderma
3) By End User: Hospital, Pharmaceutical Stores, Other End Users
Subsegments:
1) By Medication: Immunosuppressants, Antifibrotic Agents, Vasodilators, Corticosteroids, Pain Relievers
2) By Surgery: Lung Transplantation, Other Surgical Interventions
3) By Other Treatments: Physical Therapy, Occupational Therapy, Lifestyle Modifications, Alternative Therapies
What Regions Are Steering Growth in the Scleroderma Sector?
North America was the largest region in the scleroderma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the scleroderma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
How Can We Define the Scleroderma Market and Its Key Components?
Scleroderma is a rare, chronic autoimmune disease characterized by the abnormal growth of collagen, a protein that forms the structure of the skin and other tissues. The different treatments cure or halt excessive collagen production, effectively manage symptoms, and reduce the risk of complications associated with scleroderma.
Browse Through More Similar Reports By The Business Research Company:
Dermatology OTC Medications Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/dermatology-otc-medications-global-market-report
Dermatology Devices Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/dermatology-devices-global-market-report
Dermatology Endoscopy Devices Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/dermatology-endoscopy-devices-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
